Background. Studies of the transmissibility of hepatitis B virus (HBV) in occult hepatitis B (OHB) through blood transfusion are scarce. We aimed to determine the transmissibility of HBV in blood donors with OHB through transfusion in animal and human studies.
Background. Studies of the transmissibility of hepatitis B virus (HBV) in occult hepatitis B (OHB) through blood transfusion are scarce. We aimed to determine the transmissibility of HBV in blood donors with OHB through transfusion in animal and human studies.
Methods. Among 217,595 blood donors, 67 donors with OHB were identified. Four chimeric mice populated with human hepatocytes were inoculated with 2 donor serum samples. Serial serum and liver HBV DNA levels were measured. Forty-nine recipients of blood transfusions traced from 10 donors with OHB (9 of whom were positive for antibody to hepatitis B surface antigen [anti-HBs]) were tested for HBV infection. Homology and phylogenetic analyses between the HBV genomic sequences of donors and recipients were performed.
Results. Serum HBV DNA was detectable (10 4 copies/mL) in 1 mouse at weeks 5 and 7 after inoculation. Total HBV DNA and HBV replication template (covalently closed circular DNA) and hepatitis B core antigen were detected in the mouse liver. After transfusion, 45 recipients (91.8%) had no HBV infection (ie, they tested negative for hepatitis B surface antigen and HBV DNA). Four tested positive for HBV DNA. In 3 recipients, 83%-86% homology and distant phylogenetic relatedness with their donor HBV excluded transmission through transfusion. The remaining recipient HBV had 95% sequence homology with her donor HBV, compatible with acquisition of HBV infection from the transfusion. High anti-HBs levels in 7 other recipients suggested recent transfusion-related HBV immune response.
Conclusions. OHB donor blood infectivity was shown in our animal and human studies. However, the risk of HBV transmission in humans was low, especially from blood products obtained from donors with OHB who were anti-HBs positive.
Occult hepatitis B (OHB) virus infection is defined as having detectable hepatitis B virus (HBV) DNA in the serum or livers of subjects who test negative for the hepatitis B surface antigen (HBsAg). Owing to the extremely low serum HBV DNA level (usually ,100 IU/ mL) [1] , which requires highly sensitive assays to confirm the diagnosis, accurate data on the prevalence and transmissibility of OHB are very limited. The latter issue is of particular importance in improving transfusion safety. Posttransfusion acute hepatitis B has been reported to occur at a rate of 0.9% [2] , even after the implementation of serological screening for HBV.
Current information on the transmissibility of OHB through transfusion mainly relies on a few case series in which the possible link has not been clearly established by strict viral sequence comparisons between the HBV strains in the donors and the recipients. OHB is not a common entity in most countries, with a typical prevalence of ,1% [3] [4] [5] [6] . Identification of a blood donor with OHB requires considerable time for performance of nucleic acid testing (NAT) followed by extremely sensitive polymerase chain reaction (PCR) assays. These also require a high expenditure on resources. Once the donated blood is identified as OHB positive, it is discarded for obvious ethical reasons. Retrospective tracing studies are difficult to conduct because of the time lag between identification of the OHB products and contact of recipients. In addition, in areas where HBV is highly endemic, a large proportion of the population would have been naturally infected with or vaccinated against HBV.
We conducted the present study to determine the transmissibility of HBV from donors with OHB in 2 parts: (1) a chimeric mice study, to determine whether serum obtained from donors with OHB was infectious; and (2) a recipient look-back study to determine whether OHB-containing blood components were transfusion-transmissible in human recipients.
SUBJECTS AND METHODS

Subjects
The present study recruited all healthy blood donors found to have OHB during the period from 1 April 2007 through 31 January 2009 in the Hong Kong Red Cross Blood Transfusion Service. These subjects were identified by testing their blood samples for HBsAg (Prism HBsAg; Abbott Laboratories) and NAT for HBV DNA (Procleix Trigis system; Chiron; 95% detection limit, 12.2 IU/mL). All HBsAg-negative and HBV DNApositive samples had HBV DNA levels measured by real-time PCR in the Mx4000 Multiplex Quantitative PCR System (Stratagene), using primers and 6-carbosyfluorescein (FAM)-labeled TaqMan probe targeting to conserved regions in the HBV surface gene, as described previously [7] .
Of 217,595 donors, 67 subjects with OHB (0.031%) were identified. They were all negative for antibodies to human immunodeficiency virus and hepatitis C virus. Of these 67 subjects with OHB, 44 consented to participate in this study for the following additional tests: determination of the HBV DNA level, with the Artus HBV RG assay (Qiagen), which has a linear range of detection of 1.1 IU/mL to .4 3 10 9 IU/mL; assessment for antibodies to HBsAg (anti-HBs) and hepatitis B core antigen (anti-HBc; Roche Diagnostics); the chimeric mice study; and the recipient look-back study with HBV genome sequencing.
Chimeric Mice Study
Two donor samples indicating OHB-1 with undetectable anti-HBs and 1 with anti-HBs titer >10 IU/L (conventionally taken as ''protective'' against HBV infection)-were used to inoculate 4 chimeric mice (2 mice for each sample). These were severe combined immunodeficiency (SCID) mice transgenic for the urokinase-type plasminogen activator gene (uPA1/1/SCID1/ 1 mice), with the livers replaced by human hepatocytes [8] (Phoenix Bio). Human serum albumin produced by human hepatocytes was measured by enzyme-linked immunosorbent assay (Bethyl Laboratories). One hundred microliters of the donor serum, after 10-fold concentration, were intravenously injected into the mice. Serum samples were taken weekly from the mice from week 4-to 9 after inoculation. At week 9, the mice were killed for liver immunostaining and intrahepatic HBV DNA and covalently closed circular DNA (cccDNA) measurements. HBV DNA levels were quantified by real-time PCR targeting a small S region [9] , with the sensitivity of 1000 copies/ mL (200 IU/mL). The cccDNA, replicative template of HBV was quantified by real-time detection-PCR using a set of conserved primers [10] . Animal protocols were performed in accordance with guidelines for animal experimentation.
Liver sections were blocked with antibody diluent (Dako), incubated with rabbit anti-HBc (Dako,) at room temperature for 1 h, washed in phosphate-buffered saline, and then incubated with goat anti-rabbit immunoglobulin G conjugated with Cy3 (Chemicon international) or goat anti-human albumin labeled with fluorescein isothiocyanate (Bethyl Laboratories). Sections were washed with phosphate-buffered saline and observed in a fluorescent microscope (Eclipse E800M; Nikon).
Look-Back Study
Data tracing of all recipients of blood components from the 44 donors with OHB were retrieved from the database of the Hong Kong Red Cross Blood Transfusion Service. Data obtained included sex, age, the date and type of blood products transfused, indication for transfusion, the nature of the illness, and HBsAg status prior to the targeted (look-back) transfusion.
Two genomic regions (pre-S and core) were sequenced from the serum of the 44 donors with OHB. In brief, HBV DNA was extracted from their serum samples using the QIAamp MinElute Virus Vacuum Kit (Qiagen). The pre-S and core regions were amplified by nested PCR, and the 2 resulting amplicons, covering the pre-S and core regions at nt 2814-237 and 1607-2385, respectively, were sequenced bi-directionally. These 2 most variable HBV regions [1, 11] were used for homology and phylogenetic comparisons between paired donors and recipients strains. Thirty-one of the 44 donors with OHB had successful viral sequencing results at either the pre-S or core regions. Recipients of transfusions from these 31 donors with OHB were contacted. HBsAg, anti-HBs, anti-HBc, and HBV DNA levels (determined as described above) were checked in recipients who consented to take part in the study. For recipients with detectable HBV DNA, the pre-S and core regions were also sequenced by PCR. Viral sequence homology of the donor and recipient strains was performed using the CLUSTAL X program [12] . Genetic distances were estimated by the maximum composite likelihood method, and phylogenetic trees were constructed by using the neighbor-joining method, using the Molecular Evolutionary Genetics Analysis (MEGA) software, version 4 [13] . Bootstrap resampling tests were performed 1000 times to confirm the reliability of the phylogenetic tree, and values .70% were considered to be significant [14, 15] . The presence of the common surface gene mutants (G145R) were determined by PCR sequencing using primers spanning the HBV surface gene at nucleotides 426-600 (amino acid residues, 134-148).
The study was approved by the Institutional Review Board of the University of Hong Kong and the Hospital Authority Hong Kong West Cluster. Written, informed consent was obtained from both the donors and recipients. For those recipients aged ,18 years, consent was obtained from parents.
Statistical Analysis
The present study was descriptive in nature. Continuous variables were expressed as mean values with standard deviations and ranges.
RESULTS
Forty-four of the 67 identified OHB donors consented to have additional blood samples obtained for further studies. Thirtythree donors (75%) had anti-HBs levels >10 IU/L. The donors' demographic characteristics, serologic parameters, and HBV DNA levels are listed in Table 1 .
Chimeric Mice Study
Serum samples from 2 randomly selected donors (Rx5 and Rx7) with HBV DNA levels of 9.1 and 11.0 IU/mL, respectively, and anti-HBs levels of 34 IU/L and below the detection limit, respectively, were inoculated into 4 mice (2 mice for each serum sample at the DNA amount of 52.8 and 63.8 copies). Serum HBV DNA was detectable in 1 mouse (PXB [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] , which was inoculated with serum with undetectable anti-HBs from donor Rx7 at weeks 5 and 7 (2.4 3 10 4 and 2.0 3 10 4 copies/mL, respectively). The other 3 mice had no detectable serum HBV DNA up to 9 weeks. Total DNA and cccDNA (0.0458 and 0.0103 copies/cells, respectively) were detected in the liver of the PXB 8-22 mouse, whereas HBV DNA and cccDNA were not detectable in the livers of the other 3 mice. The immunofluorescent microcopy for hepatitis B core antigen (HBcAg) and human albumin in the liver tissues showed that the human hepatocytes expressed HBcAg (Figure 1 ).
Look-Back Study
Thirty-one donors with OHB had successful viral sequence generation. Two hundred seventy-two recipients who had received blood products within 3 years from these 31 donors with OHB were identified. Forty-nine recipients from 10 donors were successfully traced and consented to participate in the study. The remaining 223 recipients were not being able to undergo further investigations because they could not be contacted (n 5 46), refused to participate in the study (n 5 30), or died (n 5 147). The causes of death for these 147 subjects were traced successfully. Only 16 deaths (10.9%) were liver related (3 recipients died of hepatitis C virus-related cirrhosis and/or liver cancer, and 13 recipients were known to have chronic HBV infection before transfusion and died of HBV related cirrhosis and/or liver cancer). None died because of fulminant HBV infection.
Detailed demographic characteristics and clinical, serological, and virological parameters of the 10 donors with OHB and the 49 recipients (ratio of male to female subjects, 24:25) are listed in Table 2 . All 10 donors were repeated donors. The sample with which OHB was first diagnosed by NAT is defined as the ''index sample''; the sample from the donation received by the 49 recipients is the ''look-back sample'' (HBV DNA levels were available in some cases); the sample taken when they were recalled for further study is the ''sample at the time of further investigations.'' The median age of the recipients was 49.9 years (range, 3.1-87.4 years). Fifteen recipients were immunocompromised because they had undergone organ transplantation with immunosuppressive therapy, had a hematologic malignancy, or had end-staged renal failure.
Twenty recipients (40.8%) were positive for immunoglobulin G anti-HBc (15 with anti-HBs) ( Table 2 ). Thirteen (26.5%) had detectable anti-HBs levels but no anti-HBc, suggesting HBV vaccination. Nine of these 13 recipients were aged ,35 years. Both anti-HBc and anti-HBs were undetectable in 16 recipients (32.7%), who were considered to be susceptible to HBV infection but noninfected. Only the 15 recipients carrying both anti-HBc and anti-HBs were considered possibly HBV infected by transfusion, and among these, 2 (Rx69 and Rx96) were found to be HBV DNA positive (HBV DNA level, 9.3 and 14 IU/mL, respectively), indicating an OHB carrier state. The viral sequence homology between the recipients and donors HBV was 83% and 95%, respectively, with values confirmed by the phylogenetic analyses ( Figure 2 ). Another 2 recipients (Rx42 and Rx70) tested positive for HBsAg with detectable HBV DNA, indicating chronic HBV carriage (one was immunocompromised [viral load, 7.3 3 10 7 IU/mL]; the other had a viral load of 33 IU/mL). The viral sequence homology for these 2 recipients' and donors' HBV was only 88% and 86%, respectively, with values confirmed by the phylogenetic analyses ( Figure 2 ). The liver biochemistries of these 4 recipients were all normal.
Of the remaining 45 recipients, 16 had undetectable anti-HBc and anti-HBs; 3 were positive for anti-HBc, but anti-HBs was undetectable; 13 had undetectable anti-HBc but were positive for anti-HBs; and 13 were positive for both anti-HBc and anti-HBs (Table 2 ). Of the 26 recipients with positive anti-HBs, 8 had moderately high anti-HBs titers (>200 IU/mL). Two (Rx39 and Rx66) of these 8 recipients were negative for anti-HBc, and 6 (Rx40, Rx47, Rx67, Rx71, Rx95, and Rx97) were positive for anti-HBc. One 12-year-old recipient (Rx66) had an anti-HBs titer of 412 IU/L tested 26 months after transfusion. The other 7 recipients (age, 47-75 years) had anti-HBs levels between 299 and .1000 IU/L tested 20-52 months after transfusion. These 7 recipients received blood components carrying HBV DNA in all tested donations (5-27 /mL) from 4 donors (Rx36, Rx34, Rx58, and Rx15). Only 6 of the 27 recipients of transfusions from these 4 donors remained susceptible and noninfected (ie, negative for both anti-HBc and anti-HBs).
There were 223 recipients for whom further investigations were not performed. Twenty-four were HBsAg positive and 199 had unknown HBsAg status before transfusions. Of these 199 recipients, 24 underwent HBsAg testing after transfusions. Twenty-three of these 24 recipients were negative for HBsAg. The remaining recipient (who died of lung cancer 4 months after the transfusion) was positive for HBsAg.
DISCUSSION
In the present study, we demonstrated in the chimeric mice that serum obtained from donors with OHB with undetectable anti-HBs could be infectious. Serum HBV DNA was detected in 1 infected mouse, and more importantly, intrahepatic HBV DNA, cccDNA (the viral template in hepatocyte nucleus for viral transcription), and HBcAg (the viral protein) were found in the human hepatocytes of the mouse liver. On the contrary, the sample with positive anti-HBs titer did not infect the mice. Additional animal studies using chimeric mice model should be performed with more samples from donors with OHB, with and without anti-HBs, to confirm our preliminary finding.
It has been shown that anti-HBc-positive blood products can cause acute HBV infection in recipients [16] [17] [18] [19] . The infectivity of anti-HBs-positive blood products is still not well defined in humans [20] . Of the 49 recipient follow-up samples, 4 were positive for HBV DNA. Two were HBsAg positive, indicating chronic hepatitis B carriage; 2 were HBsAg negative, indicating OHB. The viral sequence homology of only 83%-86%, confirmed by the distant phylogenetic relatedness between donor and recipient strains, excluded a transfusion origin in 3 of these 4 cases. One of the 3 recipients (Rx42) was likely to have experienced HBV reactivation after receiving chemotherapy for non-Hodgkin lymphoma. For the fourth recipient (Rx96), who was negative for HBsAg, with 95% homology in the highly variable pre-S genomic between the donor and recipient HBV (Figure 2) , it is probable that this immunocompetent recipient acquired the HBV infection through the blood transfusion from a donor with OHB who had undetectable anti-HBs titer in the index sample and low titer (32.7 IU/L) in the sample at the time of further investigations. Discounting the 3 recipients who were probably infected with HBV before transfusion, transmission of HBV resulting in chronic HBV disease was possible but uncommon (1 [2.2%] of 46 recipients). This may be an underestimation, because 13 of the recipients were positive for anti-HBs but negative for anti-HBc, possibly because of previous HBV vaccination. The chronic HBV disease rate for the remaining 33 recipients who were susceptible to HBV infection would therefore be 3.0% (1 of 33 recipients).
Moderately high anti-HBs levels (>200 IU/mL) were found in 8 recipients ( Table 2 ). One 12-year-old recipient (Rx66) with an anti-HBs titer of 412 IU/mL might have the high titer because of comparatively recent HBV vaccination during childhood. The high anti-HBs levels in the remaining 7 adult recipients (age, .45 years) in samples collected 20-52 months after transfusion with blood components from 4 donors was suggestive of a relatively recent anti-HBs immune response secondary to exposure or re-exposure to HBV. (Of the 4 donors, 2 had undetectable anti-HBs in the index samples; all 4 were positive for anti-HBs at the time of additional investigations for the present study). The recent anti-HBs immune response is compatible with the transfused blood products carrying either circulating viral particles or very low level of the otherwise undetectable free HBsAg. Although not directly indicative of infectivity, it constitutes supportive evidence of potential infectivity of HBV DNA-positive blood products even in the presence of anti-HBs. Future studies correlating the detection of HBV DNA over time with respect to the timing of increase of anti-HBs levels in recipients are required to verify this hypothesis.
Nevertheless, the relative rarity of HBV transmission from donors with OHB held true for different scenarios. These included recipients who were children or elderly (4 recipients were aged ,7 years, 1 was aged 12 years, and 10 were aged .65 years in the present study) ( Table 2 ). Of the 15 immunocompromised recipients, none acquired HBV from transfusion (except 1 who had probably OHB before transfusion, with reappearance of HBsAg after chemotherapy, suggesting reactivation) [21] .
This low infectivity may only be applicable to donors with OHB who are positive for anti-HBs (75% of all 44 donors [ Table 1 ] and 90% of the 10 donors in the donor-recipient pairs [ Table 2 ] were positive for anti-HBs). According to another study [22] , more than one-half (57.8%) of subjects with OHB were anti-HBs positive. It has been suggested that the risk of HBV transmission is low for blood products from anti-HBspositive donors with OHB [23, 24] . A recent study reported a case of HBV transmission from an anti-HBs positive donor to two recipients when the low level of anti-HBs was insufficient to neutralize an increased level of HBV DNA [25] .
The present study has 2 limitations. First, 147 recipients had died, making a complete recipient-tracing not possible. However, according to data on the causes of death, it appeared unlikely that the deaths were related to the transfusions. Second, clinical information with regard to the disease status, including liver function tests and liver histology, was not addressed in the present study. However, those were studied in detail in a previous study of ours: subjects with OHB subjects have normal liver function test results and nearly normal liver histology findings [26] .
In conclusion, blood taken from donors with OHB was shown to be potentially infectious in our animal and human studies. However, the risk of chronic hepatitis B transmission through transfusion of blood donated by anti-HBs-positive donors with OHB in human remained low.
